RNA Supply Chain Videos

  1. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

  2. Don't Ignore These Functional Areas In Your RNA Therapeutic's Regulatory Story 5/10/2024

    Explore two functional areas that Advancing RNA panelists consider most essential to telling an RNA product’s “story” thoroughly to regulators.

  3. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

  4. The 3 C's Of mRNA-LNP Material Sourcing

    In response to an audience poll question gauging which cGMP materials have proven the most difficult to source, our speakers provide additional clarity around which IVT & LNP-related materials today are more “commoditized”.

  5. End-To-End Cold Chain Management: A Next-Generation Approach 2/26/2024

    Three experts in cold chain management walk through the advantages of end-to-end platforms for bulk drug substance management.

  6. Is The IVT Reaction A Coy Mistress? The Knowns & Unknowns 4/24/2023

    In this Bioprocess Online Live panel, we discuss two experts' perspectives on the current state of the mRNA supply chain for critical raw materials and manufacturing supplies and where pain points still exist.

  7. Strategies To De-Risk Next-Gen mRNA Raw Materials 12/3/2025

    In this Advancing RNA Live clip, Khaled Yamout and Sanofi’s Francoise Ribes share the quality considerations that are top of mind when evaluating a novel raw material, as well as how the broader industry (i.e., standard setting organizations, suppliers, and biotechs) can arrive at a clearer understanding of a material’s quality.

  8. Next-Generation RNA Modality Supply Considerations

    Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.

  9. The Road To Metric-Ton siRNA Production: Is Enzymatic Ligation Ready For Commercial Volume? 3/27/2026

    Can we actually achieve metric-ton siRNA production today using enzymatic ligation? While the ligation step is highly scalable, upstream "blockmer" synthesis remains the primary bottleneck. Advancing RNA Live panelists Claire McCleod and Jill Caswell discuss the shift from "scaling out" to "scaling up" and lessons learned in the process of achieving larger scale production. 

  10. Addressing mRNA's Scalability And Supply Challenges 3/14/2022

    Tune in as Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx share supply chain and manufacturing capacity constraints in the face of the urgency to address COVID-19. This is an excerpt from the Bioprocess Online Live event - mRNA Manufacturing: Bright Future, Big Challenges.